Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EW Healthcare Partners Adds Women’s Health Heft With TherapeuticsMD Buyout

Executive Summary

Deal Snapshot: The UK-based private equity firm will acquire troubled specialty pharma TherapeuticsMD for roughly $177m, after the company’s three-product portfolio yielded revenues of $85.8m in 2021.

You may also be interested in...



Deal Watch: Organon Obtains Rights To Perjeta, Prolia/Xgeva Biosimilars From Shanghai Henlius

Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.

Finance Watch: Phathom IPO Meets Pricing Goal; Cabaletta, TFF Offerings Go Low

Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.

Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel